These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 11145489)

  • 1. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.
    ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy
    Lancet; 2000 Dec; 356(9247):2037-44. PubMed ID: 11145489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.
    Granada JF; Kleiman NS
    Am J Cardiovasc Drugs; 2004; 4(1):31-41. PubMed ID: 14967064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial.
    Biondi-Zoccai GG; Valgimigli M; Sheiban I; Margheri M; Marzocchi A; Prati F; Vischi M; Lettieri C; Violini R; Sardella G; Stabile A; Clementi F; Romeo F; Colombo A; Sangiorgi G
    J Cardiovasc Med (Hagerstown); 2008 Sep; 9(9):957-62. PubMed ID: 18695440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention.
    O'Shea JC; Buller CE; Cantor WJ; Chandler AB; Cohen EA; Cohen DJ; Gilchrist IC; Kleiman NS; Labinaz M; Madan M; Hafley GE; Califf RM; Kitt MM; Strony J; Tcheng JE;
    JAMA; 2002 Feb; 287(5):618-21. PubMed ID: 11829701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial.
    O'Shea JC; Hafley GE; Greenberg S; Hasselblad V; Lorenz TJ; Kitt MM; Strony J; Tcheng JE;
    JAMA; 2001 May; 285(19):2468-73. PubMed ID: 11368699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.
    Lancet; 1997 May; 349(9063):1422-8. PubMed ID: 9164315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial.
    Tcheng JE; Lim IH; Srinivasan S; Jozic J; Gibson CM; O'Shea JC; Puma JA; Simon DI
    Circ Cardiovasc Interv; 2009 Feb; 2(1):43-51. PubMed ID: 20031692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
    Dery JP; Campbell ME; Mathias J; Pieper KS; Harrington RA; Madan M; Gibson CM; Tolleson TR; O'Shea JC; Tcheng JE;
    Catheter Cardiovasc Interv; 2007 Jul; 70(1):43-50. PubMed ID: 17203469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.
    Puma JA; Banko LT; Pieper KS; Sacchi TJ; O'Shea JC; Dery JP; Tcheng JE
    J Am Coll Cardiol; 2006 Feb; 47(4):715-8. PubMed ID: 16487833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa.
    O'Shea JC; Tcheng JE
    Expert Opin Pharmacother; 2002 Aug; 3(8):1199-210. PubMed ID: 12150697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.
    Ibbotson T; McGavin JK; Goa KL
    Drugs; 2003; 63(11):1121-63. PubMed ID: 12749745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes.
    Plosker GL; Ibbotson T
    Pharmacoeconomics; 2003; 21(12):885-912. PubMed ID: 12908844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention.
    O'shea JC; Madan M; Cantor WJ; Pacchiana CM; Greenberg S; Joseph DM; Kitt MM; Lorenz TJ; Tcheng JE
    Am Heart J; 2000 Dec; 140(6):834-9. PubMed ID: 11099985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    EPISTENT Investigators
    Lancet; 1998 Jul; 352(9122):87-92. PubMed ID: 9672272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial.
    Blankenship JC; Tasissa G; O'Shea JC; Iliadis EA; Bachour FA; Cohen DJ; Lui HK; Mann T; Cohen E; Tcheng JE;
    J Am Coll Cardiol; 2001 Sep; 38(3):653-8. PubMed ID: 11527612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eptifibatide in Percutaneous Coronary Intervention: The ESPRIT Trial Results.
    O'Shea JC; Tcheng JE
    Curr Interv Cardiol Rep; 2001 Feb; 3(1):62-68. PubMed ID: 11177721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study.
    Fernandes LS; Tcheng JE; O'Shea JC; Weiner B; Lorenz TJ; Pacchiana C; Berdan LG; Maresh KJ; Joseph D; Madan M; Mann T; Kilaru R; Hochman JS; Kleiman NS;
    J Am Coll Cardiol; 2002 Sep; 40(6):1085-91. PubMed ID: 12354432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial.
    PRICE Investigators
    Am Heart J; 2001 Mar; 141(3):402-9. PubMed ID: 11231437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
    Curran MP; Keating GM
    Drugs; 2005; 65(14):2009-35. PubMed ID: 16162023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.